CliveSZentMD
Hematology • Rochester, NYHematologic Oncology
Professor, Wilmot Cancer Institute, University of Rochester
Dr. Zent is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
601 Elmwood Ave
# 704
Rochester, NY 14642Phone+1 585-273-5823Fax+1 585-273-1051
Education & Training
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 1996 - 1997
University of ChicagoFellowship, Hematology and Medical Oncology, 1993 - 1996
University of Cape TownMMed, 1987 - 1990
University of the WitwatersrandClass of 1983
Certifications & Licensure
NY State Medical License 2013 - 2025
MN State Medical License 2003 - 2014
AR State Medical License 1996 - 2003
IL State Medical License 1993 - 1999
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Clinical Trials
- A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated Start of enrollment: 2004 Jul 01
- Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia Start of enrollment: 2004 Dec 01
- Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia Start of enrollment: 2008 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- 53 citationsOutcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.Anthony R. Mato, Lindsey E. Roeker, John N. Allan, John M. Pagel, Danielle M. Brander
American Journal of Hematology. 2018-11-01 - 72 citationsDirect and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuz...Clive S. Zent, Charla R. Secreto, Betsy LaPlant, Nancy D. Bone, Timothy G. Call
Leukemia Research. 2008-12-01 - 66 citationsClinical effects of oral green tea extracts in four patients with low grade B-cell malignanciesTait D. Shanafelt, You Kyoung Lee, T. G. Call, Grzegorz S. Nowakowski, David Dingli
Leukemia Research. 2006-06-01
Journal Articles
- CD20 and CD37 Antibodies Synergize to Activate Complement by Fc-Mediated ClusteringRonald P Taylor, Clive S Zent, Haematologica
Abstracts/Posters
- A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Clive S Zent, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug ChoiceClive S Zent, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Wilmot Cancer Institute Secures $13.6 Million in GrantsAugust 8th, 2022- Shingles Vaccine Shows Promise in Lymphoma PatientsNovember 10th, 2020
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
